ArticleDermatology and therapy2025

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.

David M Pariser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.